Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Neuropsychiatry and Clinical Neurosciences|February 7, 2009
White matter anisotropy and depression symptoms in patients with HIVClifford A Smith, Glenn T Stebbins, Russell E Bartt, et al.AIDS Research and Therapy|April 14, 2005
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimenHeather A Baird, Andre J Marozsan, Michael M Lederman, et al.AIDS (London, England)|September 27, 2005
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patientsMelanie A Thompson, Harold A Kessler, Joseph J Eron, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
HIV-associated alterations in normal-appearing white matter: a voxel-wise diffusion tensor imaging studyGlenn T Stebbins, Clifford A Smith, Russell E Bartt, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 6, 2003
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic courseAllan R Tenorio, Kimberly Y Smith, Daniel R Kuritzkes, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 5, 2002
Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapyRohit Talwani, Oluwatoyin M Falusi, Carlos F Mendes de Leon, et al.AIDS (London, England)|April 13, 2004
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up studyCharles Hicks, Martin S King, Roy M Gulick, et al.The Journal of Infectious Diseases|January 15, 2004
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trialJoseph J Eron, Judith Feinberg, Harold A Kessler, et al.The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.Pageof 2